How optimizing RBQM risk detection reduces the efforts caused by false signals.
Jonathan Rowe, PhD, MS, MA
Advertisement
Jonathan Rowe, PhD, MS, MA, has worked in the pharmaceutical industry across clinical, quality and corporate teams for over 25 years. He currently leads ZS’s clinical development quality, operations and risk management functions from the New York office.
Articles by Jonathan Rowe, PhD, MS, MA
Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.
Optimizing feasibility through increased data collection.
Applied Clinical Trials
A case study by Pfizer & The Avoca Group on the development of an overarching strategy for Pfizer’s clinical trial quality metrics.
Advertisement
Latest Updated Articles
The Eradication of False Signals in MonitoringSeptember 7th 2022
Quality Metrics for Clinical TrialsJuly 8th 2015
- Towards Data-Driven Clinical Trial Planning and Strategy
December 16th 2021
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial
2
FDA Reportedly Pauses Commissioner’s National Priority Voucher Pilot as Existing Reviews Continue
3
Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices
4
How Inconsistent Screening Shapes Which Oncology Patients Get Flagged for Trials
5